# Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

> **NCT02769065** · PHASE1 · TERMINATED · sponsor: **Takeda** · enrollment: 179 (actual)

## Conditions studied

- Alzheimer Disease
- Healthy Volunteers

## Interventions

- **DRUG:** TAK-071
- **DRUG:** Donepezil
- **DRUG:** TAK-071 Placebo
- **DRUG:** Donepezil Placebo

## Key facts

- **NCT ID:** NCT02769065
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05-05
- **Primary completion:** 2017-06-08
- **Final completion:** 2017-06-08
- **Target enrollment:** 179 (ACTUAL)
- **Why stopped:** Terminated prematurely as data from cohort no longer needed due to indication change.
- **Last updated:** 2019-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02769065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02769065, "Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02769065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*